Form 4: Ionis Pharmaceuticals EVP Eric Swayze Reports Stock Transactions

EVP of Research at Ionis Pharmaceuticals, Eric Swayze, reports acquisition and disposal of common stock and restricted stock units.

Summary

• Eric Swayze, EVP of Research at Ionis Pharmaceuticals, reported transactions involving Ionis common stock and restricted stock units.
• On October 15, 2024, Swayze acquired 125 shares of common stock through the vesting of restricted stock units.
• Also on October 15, 2024, Swayze disposed of shares to cover tax withholding obligations.
• On October 16, 2024, Swayze sold 53 shares of common stock at a price of $38.313 per share.
• Following these transactions, Swayze directly owns 34,907 shares of common stock.
• Swayze also indirectly owns 210 shares of common stock and 426 restricted stock units through his son.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel at Ionis Pharmaceuticals.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company executive.

Key Dates